• Record: found
  • Abstract: found
  • Article: not found

Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.

Leukemia & Lymphoma

Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Survival Analysis, administration & dosage, Pyrazines, Prognosis, Polyethylene Glycols, metabolism, Myeloma Proteins, mortality, drug therapy, diagnosis, Multiple Myeloma, Models, Statistical, blood, Immunoglobulin Light Chains, Humans, Follow-Up Studies, analogs & derivatives, Doxorubicin, Dexamethasone, Boronic Acids, therapeutic use

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      In myeloma, achievement of very good partial response (VGPR) post-transplant is associated with prolonged overall (OS) and progression-free survival (PFS). In this study of bortezomib, pegylated liposomal doxorubicin, and dexamethasone (VDD) in 40 patients with newly diagnosed myeloma (median follow-up 45.1 months), 2-/4-year OS estimates were 95.7%/86.5% versus 82.4%/58.2% for patients achieving ≥VGPR versus 

      Related collections

      Author and article information



      Comment on this article